Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502124 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 78
- Enrollment target
NCT01502124 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 78 participants.
The verdict
NCT01502124, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 78 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.
Interventions
- DRUG somatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2001-05-08 |
| Est. Completion | 2003-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01502124
The ClinicalTrials.gov registry entry for NCT01502124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin is the first listed.
NCT01502124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01502124 about?
NCT01502124 is a clinical study titled "Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency". This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.
What is the current status of trial NCT01502124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 78 participants. The study started on 2001-05-08. Estimated completion is 2003-03-05.
What interventions are being tested in trial NCT01502124?
The interventions under investigation include: somatropin (DRUG).
Who is sponsoring clinical trial NCT01502124?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.